A number of brokerages have recently commented on PAHC. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research note on Monday, June 16th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research note on Thursday, August 28th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price target for the company from $25.00 to $35.00 in a research note on Monday, July 7th. Bank of America increased their price target on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. Finally, Zacks Research cut Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 28th.